Newsroom

ScaleReady and its partners have awarded four G-Rex® Grants totaling over $1M to leading researchers at USC and CHLA to accelerate innovative CAR-T and T cell therapy programs targeting solid tumors and pediatric cancers.

A2 Biotherapeutics receives a $300,000 G-Rex® Grant to support scalable CAR-T manufacturing and process development using its Tmod™ platform for solid tumor therapies.

March Biosciences has been awarded a $200,000 G-Rex® Grant from ScaleReady and partners to streamline cGMP manufacturing of its MB-105 CAR-T therapy for CD5-positive T-cell lymphomas.

Josh Ludwig - Global Commercial Director at ScaleReady talks to IBTV about G-Rex, open collaboration and ScaleReady's current projects at Phacilitate's - Advanced Therapies Week at the Kay Bailey Hutchison Convention Center, Dallas, Texas, 20 – 23 January 2025.

Learn how BrainChild Bio is accelerating its groundbreaking CAR-T therapy for pediatric brain cancer with a $300,000 G-Rex® Grant supported by ScaleReady and its partners.

Josh Ludwig of ScaleReady unpacks how the pharmaceutical industry is tapping into innovations from adjacent sectors to revolutionize drug development and manufacturing. From automation and AI-driven analytics to advanced bioprocessing techniques, discover how lessons from tech, automotive, and other industries are accelerating efficiency, scalability, and accessibility in pharma. Learn why integrating outside expertise isn’t just a trend—it’s the key to driving the next wave of breakthroughs in medicine.

In the latest installment of The Sustainability Series, industry leaders explore why sustainability in biotech goes beyond environmental responsibility—it’s about long-term viability, ethical production, and global health equity. Discover how companies are reflecting on current practices, rethinking supply chains, and reforming strategies to create a more resilient and responsible future for life sciences. Learn why a shift toward sustainability isn’t just a choice—it’s an imperative for innovation and impact.

In this deep dive into cutting-edge biotech, Wilson Wolf explores the transformative potential of scalable cell manufacturing. Discover how innovative technologies, like the G-Rex platform, are redefining efficiency, overcoming production bottlenecks, and paving the way for greater access to life-saving cell therapies. Learn how advancements in automation, standardization, and cost-effective solutions are accelerating the future of cell therapy—bridging the gap between groundbreaking science and real-world patient impact.

ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.

The CGT sector is making significant strides, highlighted by the FDA approval of the first CRISPR therapeutic. Experts, including Josh Ludwig, Global Director, Commercial Operations, ScaleReady, predict continued growth and innovation in 2024 and beyond. Key challenges include manufacturing capacity, standardization, and delivery systems. However, advancements in technology and partnerships between developers and manufacturers offer promising solutions.

MaxCyte and ScaleReady have partnered for the G-Rex Grant Program, which aims to accelerate cell and gene therapy development. The program offers resources, tools, and expertise to recipients. MaxCyte's electroporation technology and ScaleReady's manufacturing solutions are key components of the program. The goal is to reduce barriers to entry for CGT companies and expedite the development of life-saving therapies.

Bio-Techne, Wilson Wolf, and CellReady awarded a $300,000 G-Rex Grant to Stanford Medicine's LCGM for CAR-T cell therapy manufacturing. The grant is part of a $20 million initiative to support CGT development. Eligible recipients receive supplies, support, and discounts. Stanford Medicine LCGM plans to use the grant for a Phase I trial and potency testing. Feldman from Stanford Medicine LCGM expressed the grant's importance for future clinical trials. Wilson from Wilson Wolf praised Stanford University's reputation for innovation.